A Recombinant VSV-Vectored Vaccine Rapidly Protects Nonhuman Primates against Heterologous Lethal Lassa Fever

Vaccination of cynomolgus monkeys with a recombinant vesicular stomatitis virus vector expressing the glycoprotein precursor of LASV lineage IV strain Josiah induced fast-acting protection in monkeys challenged three or seven days later with a genetically heterologous lineage II isolate of LASV from Nigeria, while nonspecifically vaccinated control animals succumbed to challenge.